st2825 and Leukemia

st2825 has been researched along with Leukemia* in 1 studies

Other Studies

1 other study(ies) available for st2825 and Leukemia

ArticleYear
MYD88 Inhibitor ST2825 Suppresses the Growth of Lymphoma and Leukaemia Cells.
    Anticancer research, 2017, Volume: 37, Issue:11

    Myeloid differentiation primary response gene 88 (MYD88), which activates the nuclear factor kappa B (NF-κB) pathway, is important for the growth of lymphoma and leukaemia cells. In this study, we investigated the effects of ST2825, a synthetic peptidomimetic compound which inhibits MYD88 homodimerization, on their growth.. Seven lymphoma and leukaemia cell lines including TMD8, a B-cell lymphoma line with MYD88-activating mutation, were treated with ST2825 and analysed for cell proliferation and expression of NF-κB signalling-related molecules.. ST2825 suppressed the growth of all cell lines by inducing apoptosis and down-regulating phosphorylation of NF-κB pathway components inhibitor of nuclear factor kappa B kinase (IκB) and reticuloendotheliosis oncogene A (RelA), as well as of MYD88 activator Bruton tyrosine kinase (BTK), suggesting that MYD88 may affect BTK activity. ST2825 effects were specific as MYD88-targeting siRNA also suppressed phosphorylation of NF-κB signalling proteins and BTK in TMD8 cells.. ST2825 may be a novel drug targeting not only B-lymphoid malignancies with MYD88 mutations, but also lymphoma and leukaemia with wild-type MYD88.

    Topics: Apoptosis; Cell Proliferation; Heterocyclic Compounds, 2-Ring; Humans; Leukemia; Lymphoma; Myeloid Differentiation Factor 88; Spiro Compounds; Tumor Cells, Cultured

2017